CB Therapeutics trades on the FSE under the symbol
CB Therapeutics has developed an innovative and proprietary cellular agriculture platform to efficiently research, discover, develop and produce therapeutic compounds to advance Neuroscience.
CB Therapeutics is bringing promising cannabinoid and tryptamine therapeutics to the clinic and to the market to treat depression, PTSD, opioid addiction, alcoholism, anxiety, pain and other mental healthcare and social challenges.
CB Therapeutics is producing natural molecules and their analogs as therapeutic compounds for clinical research and the commercial market. After more than four years in research and development, we have focused on the therapeutic potential of cannabinoids and tryptamines for use in the treatment of depression, PTSD, anxiety, addiction and other mental disorders. We are able to produce these phytochemicals and other promising molecules and compounds more rapidly, utilizing fewer resources, at greater yields and with more purity, consistency and efficiency than Mother Nature.
GET THE HEADLINES + UPDATES
Be the first to see new company features, exclusive interviews and breaking news. Subscribe now.